Back to results
US 10,647,766 B2Granted
Anti-CXCL12 antibody molecules and their uses
AssigneeCancer Research Technology Limited
InventorsFrances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
Life of this patent
Estimating the term…
Abstract
Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.
Claims17
An isolated anti-CXCL12 antibody molecule which specifically binds to human CXCL12, wherein the antibody molecule comprises
- (a) a heavy chain complementarity-determining region 1 (CDR-H1) having the amino acid sequence of NYGIS (SEQ ID NO:
- 12),
- (b) a heavy chain complementarity-determining region 2 (CDR-H2) having the amino acid sequence of WISAYNGNTNYAQKLQG (SEQ ID NO:
- 13),
- (c) a heavy chain complementarity-determining region 3 (CDR-H3) having the amino acid sequence of AGGVYYDYFTDY (SEQ ID NO:
- 14),
- (d) a light chain complementarity-determining region 1 (CDR-L1) having the amino acid sequence of SGSRSNIGSNSVN (SEQ ID NO:
- 15),
- (e) a light chain complementarity-determining region 2 (CDR-L2) having the amino acid sequence of NNDERPS (SEQ ID NO:
- 16), and
- (f) a light chain complementarity-determining region 3 (CDR-L3) having the amino acid sequence of AAWDDSLNVGEL (SEQ ID NO:
- 17).
9 more elements
An anti-CXCL12 antibody molecule comprising:
- a variable heavy chain (VH) polypeptide having the amino acid sequence of SEQ ID NO:
- 18, and
- a variable light chain (VL) polypeptide having the amino acid sequence of SEQ ID NO:
- 20, wherein the antibody molecule specifically binds to human CXCL12 and inhibits CXCL12-mediated biological activity.
1 more element
Dependencies are inferred from the claim text.